Comparable and high THC-to-CBD ratio products may result in small improvements in pain and increase in common adverse events<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Jan. 2, 2026 (HealthDay News) — Short-term treatment with comparable and high tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio cannabinoid products may improve pain and increase common adverse events, according to a review published online Dec. 23 in the Annals of Internal Medicine<\/em>.<\/p>\n Roger Chou, M.D., from the Oregon Health & Science University in Portland, and colleagues conducted a systematic review to update the evidence on cannabinoids for chronic pain. Cannabinoids were classified by THC-to-CBD ratio (high, comparable, or low), source, and administration method. Cannabinoids were assessed in 25 short-term (one to six months) randomized controlled trials, with 2,303 participants.<\/p>\n The researchers found that pain severity may be reduced slightly with oral synthetic\/purified high THC-to-CBD (THC only) and oromucosal, extracted, comparable THC-to-CBD ratio products (pooled differences, \u22120.78 and \u22120.54 points, respectively); moderate-to-large increases were seen in dizziness, sedation, and nausea. Nabilone moderately reduced pain severity but dronabinol did not, among THC-only products (pooled differences, \u22121.59 and \u22120.23 points, respectively). Outcomes may not be improved by low THC-to-CBD interventions. CBD alone may not increase harms, while low THC-to-CBD mixed THC\/CBD products may increase dizziness, sedation, and nausea.<\/p>\n “CBD-based products are widely available in dispensaries. Many people use these products and they think it helps,” Chou said in a statement. “Our goal is to provide some scientific basis to help people make their decisions.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required) <\/a><\/p>\n